Friday, July 18, 2025 7/18/2025

Development of a novel replicating viral RNA vaccine platform

Award Number: F32AI136371
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 02/01/2018
PERIOD OF PERFORMANCE END DATE: 08/31/2020

Group Awards By:

View Award Description

Development of a novel replicating viral RNA vaccine platform - PROJECT SUMMARY Viral replicons, or self-replicating RNA elements incapable of initiating a spreading infection, are traditionally packaged into virus particles, termed viral replicon particles (VRPs), for in vivo delivery. Alternatively, they can be encoded on a plasmid DNA and transfected for host cell nucleus-mediated launch of replicating RNA. However, concerns of anti-vector immunity with respect to the former, or genome integration in the latter approach has limited the clinical use of such technologies. Furthermore, the development of VRPs has been restricted to larger viruses that are capable of harboring additional genetic cargo. With improvements in the delivery of naked RNA, there are now opportunities to develop new viral replicons without the constraints provided by traditional delivery paradigms. By utilizing replicons derived from diverse positive- strand RNA virus families, we can exploit the various mechanisms used by the host to detect replicating viral RNA as well as the differential mechanisms of immune evasion utilized by the parental virus, to rationally design vaccines. We propose studies that will elucidate the minimal genetic elements derived from a small positive-stranded RNA animal virus that are required to replicate and express a heterologous gene from a subgenomic transcript. We will then demonstrate the translational applications towards vaccine development for Zika and tuberculosis, viral and bacterial diseases with significant public health consequences. Furthermore, we will perform comparative studies between this platform with existing platform technologies derived from other positive-strand RNA virus families with the hypothesis that each will elicit distinct innate and adaptive immune responses due to evolutionary differences of the parental viruses.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = -$4,488 )
2022	2020	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Allergy and Infectious Diseases Research	002	3	4/22/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$4,488
2022	2019	INFECTIOUS DISEASE RESEARCH INSTITUTE	1616 EASTLAKE AVE E STE 400	SEATTLE	WA	98102	KING	USA	Allergy and Infectious Diseases Research	001	2	4/22/2022	NON-COMPETING CONTINUATION	$0
2022	2018	INFECTIOUS DISEASE RESEARCH INSTITUTE	1616 EASTLAKE AVE E STE 400	SEATTLE	WA	98102	KING	USA	Allergy and Infectious Diseases Research	000	1	4/22/2022	NEW	$0
														Subtotal = -$4,488

Issue Date FY: 2021 ( Subtotal = -$23,152 )
2021	2020	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Allergy and Infectious Diseases Research	000	3	10/28/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$23,152
														Subtotal = -$23,152

Issue Date FY: 2020 ( Subtotal = $67,446 )
2020	2020	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Allergy and Infectious Diseases Research	001	3	5/27/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$67,446
2020	2019	INFECTIOUS DISEASE RESEARCH INSTITUTE	1616 EASTLAKE AVE E STE 400	SEATTLE	WA	98102	KING	USA	Allergy and Infectious Diseases Research	000	2	5/26/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $67,446

Issue Date FY: 2019 ( Subtotal = $61,610 )
2019	2019	INFECTIOUS DISEASE RESEARCH INSTITUTE	1616 EASTLAKE AVE E STE 400	SEATTLE	WA	98102	KING	USA	Allergy and Infectious Diseases Research	000	2	1/31/2019	NON-COMPETING CONTINUATION	$61,610
														Subtotal = $61,610

Issue Date FY: 2018 ( Subtotal = $58,654 )
2018	2018	INFECTIOUS DISEASE RESEARCH INSTITUTE	1616 EASTLAKE AVE E STE 400	SEATTLE	WA	98102	KING	USA	Allergy and Infectious Diseases Research	002	1	5/24/2018	NEW	$1,960
2018	2018	INFECTIOUS DISEASE RESEARCH INSTITUTE	1616 EASTLAKE AVE E STE 400	SEATTLE	WA	98102	KING	USA	Allergy and Infectious Diseases Research	000	1	12/16/2017	NEW	$56,694
2018	2018	INFECTIOUS DISEASE RESEARCH INSTITUTE	1616 EASTLAKE AVE E STE 400	SEATTLE	WA	98102	KING	USA	Allergy and Infectious Diseases Research	001	1	12/16/2017	NEW	$0
														Subtotal = $58,654

Grand Total All Awards = $160,070

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a novel replicating viral RNA vaccine platform

Award Number: F32AI136371

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 02/01/2018

PERIOD OF PERFORMANCE END DATE: 08/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer